Lexaria Bioscience Corp
LEXXW
$0.0301 19.44%
Exchange: NASDAQ | Sector: Healthcare | Industry: Biotechnology
Q1 2025
Published: Jan 10, 2025

Earnings Highlights

  • Revenue of $0.18M up 21.6% year-over-year
  • EPS of $-0.16 decreased by 23.1% from previous year
  • Gross margin of 98.5%
  • Net income of -2.70M
  • "N/A" - N/A
LEXXW
Company LEXXW

Executive Summary

Lexaria Bioscience Corp (LEXXW) reported QQ1 2025 results that feature a meaningful sequential revenue uplift but continued operating losses driven by aggressive R&D outlays. Revenue rose 21.6% year-over-year to $183,923 and 118.96% quarter-over-quarter from the Q4 2024 level of $84,000, underscoring the company’s reliance on out-licensing and technology development in a capital-light model. The gross margin remains exceptionally strong at ~98.5% due to a very low cost of revenue, while operating expenses swelled to $2.87 million as R&D accounted for the largest share of spend, signaling an ongoing push to build licensing and product pipelines for DehydraTECH.

Key Performance Indicators

Revenue
Increasing
183.92K
QoQ: 118.96% | YoY: 21.58%
Gross Profit
Increasing
181.20K
98.52% margin
QoQ: 115.72% | YoY: 23.73%
Operating Income
Decreasing
-2.69M
QoQ: -22.13% | YoY: -136.20%
Net Income
Decreasing
-2.70M
QoQ: -23.75% | YoY: -129.26%
EPS
Decreasing
-0.16
QoQ: 5.88% | YoY: -23.08%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q2 2025 0.17 -0.15 +20.0% View
Q1 2025 0.18 -0.16 +21.6% View
Q4 2024 0.08 -0.17 +2.0% View
Q3 2024 0.08 -0.13 -9.8% View
Q2 2024 0.15 -0.06 +55.7% View